Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): The ReFocus study Meeting Abstract
| Authors: | Hollebecque, A.; Dotan, E.; Liao, C. Y. A.; Roda, D.; Fontana, E.; Babiker, H.; Kim, R. D.; Oh, D. Y.; Ghiringhelli, F.; Moreno, I.; Liu, J.; Subbiah, V.; Varkaris, A.; Borad, M. J.; Cassier, P. A.; Deary, A.; Ramirez, F. T.; Ricard, F.; Jen, K. Y.; Schram, A. M. |
| Abstract Title: | Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): The ReFocus study |
| Meeting Title: | 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 211 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Oct 23-25 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-10-01 |
| Start Page: | S24 |
| End Page: | S26 |
| Language: | English |
| ACCESSION: | WOS:001345547300057 |
| DOI: | 10.1016/j.ejca.2024.114585 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 58 (PB046) -- Article number: 114585 -- Source: Wos |
